SPK transplant has no survival benefits for type 2 diabetes patients

04/18/2012 | Renal and Urology News

Data on 6,416 type 2 diabetes patients revealed those who underwent simultaneous pancreas-kidney transplantation had an 82% five-year survival rate compared with 75.5% in those who had deceased-donor kidney transplantation alone. However, researchers said the difference was related to younger donor and recipients ages in the SPK group. The study also found that the five-year death-censored graft survival was 86.2% in SPK recipients and 82.6% in those who had DDKA, a non-significant difference. The findings appear in the Clinical Journal of the American Society of Nephrology.

View Full Article in:

Renal and Urology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC